BeOne Medicines (ONC) Cost of Revenue (2017 - 2026)

BeOne Medicines (ONC) has 10 years of Cost of Revenue data on file, last reported at $167.2 million in Q1 2026.

• Quarterly Cost of Revenue rose 1.34% year-over-year to $167.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $670.8 million (up 5.77% YoY) and the FY2025 annual result came in at $668.5 million, up 12.53% from the prior year.
• Cost of Revenue grew to $167.2 million in Q1 2026 per ONC's latest filing, from $142.4 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $196.5 million in Q3 2025 and bottomed at $65.2 million in Q1 2022.
• The 5-year median for Cost of Revenue is $124.9 million (2024), against an average of $123.3 million.
• The widest annual swing landed in 2022, when Cost of Revenue jumped 99.59%; it then decreased 11.3% in 2025.
• Tracing ONC's Cost of Revenue over 5 years: stood at $73.5 million in 2022, then surged by 43.95% to $105.8 million in 2023, then surged by 51.71% to $160.6 million in 2024, then decreased by 11.3% to $142.4 million in 2025, then grew by 17.41% to $167.2 million in 2026.
• Per Business Quant, the three latest ONC Cost of Revenue figures stand at $167.2 million (Q1 2026), $142.4 million (Q4 2025), and $196.5 million (Q3 2025).

Peer Comparison